{"text": "no alzheimers patients amp caregivers dont want false hope in aducanumab being approved it will waste valuable time where alz patients could be in clinicaltrials for potential disease modifying therapies that would truly work biogen biib amyloid endalz caregiving neuro"}
{"text": "biib icer unconvinced by biogen data suggests low price for alzheimer s drug via"}
{"text": "biib biogen wont explain why fda slapped down their bid for new tysabri formulation"}
{"text": "icer releases draft evidence report on biib aducanumab for alzheimers disease estimates of small overall health gains commensurate with value based prices at traditional cost effectiveness thresholds between 2 500 8 300 per year"}
{"text": "biogens alzheimers drug may only be cost effective at 2 500 a year pharma biotech alzheimer s biib fda"}
{"text": "biib biogen s alzheimer s drug may only be cost effective at 2 500 a year"}
